Journal Mobile Options
Table of Contents
Vol. 22, No. 2-3, 2006
Issue release date: July 2006

A Randomised, Controlled Pilot Study to Investigate the Potential Benefit of Intervention with Insulin in Hyperglycaemic Acute Ischaemic Stroke Patients

Walters M.R. · Weir C.J. · Lees K.R.
To view the fulltext, log in and/or choose pay-per-view option

Individual Users: Register with Karger Login Information

Please create your User ID & Password





Contact Information











I have read the Karger Terms and Conditions and agree.

To view the fulltext, please log in

To view the pdf, please log in

Abstract

Background: Hyperglycaemia on presentation with acute ischaemic stroke (AIS) is associated with poor outcome, but intervention is unproven. We investigated the safety and tolerability of one method of glycaemic control. Methods: Patients within 24 h of AIS and plasma glucose 8–20 mmol/l were randomised to receive either rigorous glycaemic control (RC) or standard management (SM) for 48 h. RC comprised i.v. insulin at a variable rate adjusted for target glucose concentration of 5–8 mmol/l, and intravenous crystalloid. The SM group received intravenous crystalloid alone in an open-label design. Results: Thirteen patients were randomised to RC and 12 to SM (age 75 ± 6.2 years; 40% male; 20% lacunar stroke; time to treatment 8 ± 6.1 h; plasma glucose 10.6 ± 0.9 mmol/l; known diabetes 52%; NIHSS 8, range 2–28). The glucose concentration-time curve was reduced in the RC group (AUC 324 ± 15 versus 385 ± 28 h·mmol/l, p = 0.04). By 48 h, plasma glucose in both groups was 6.8 ± 1.1 and 7.5 ± 1.3 mmol/l respectively, but mean hourly insulin requirements in the RC group had dropped from 3.25 ± 0.32 units to 1.25 ± 0.5 units (p < 0.01). One transient episode of hypoglycaemic symptoms occurred in the RC group. Conclusion: Glycaemic control with sliding scale insulin for 48 h is feasible and well-tolerated after AIS. Treatment after 48 h may be unnecessary.



Copyright / Drug Dosage

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher or, in the case of photocopying, direct payment of a specified fee to the Copyright Clearance Center.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in goverment regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.

References

  1. Tissue plasminogen activator for acute ischemic stroke. The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. N Engl J Med 1995;333:1581–1587.
  2. Capes SE, Hunt D, Malmberg K, Pathak P, Gerstein HC: Stress hyperglycemia and prognosis of stroke in nondiabetic and diabetic patients: a systematic overview. Stroke 2001;32:2426–2432.
  3. Malmberg K, et al: Prospective randomised study of intensive insulin treatment on long term survival after acute myocardial infarction in patients with diabetes mellitus. BMJ 1997;314:1512–1515.
  4. Malmberg K, Ryden L, Wedel H, Birkeland K, Bootsma A, Dickstein K, Efendic S, Fisher M, Hamsten A, Herlitz J, Hildebrandt P, Macleod K, Laakso M, Top-Pedersen C, Waldenstrom A: Intense metabolic control by means of insulin in patients with diabetes mellitus and acute myocardial infarction (DIGAMI 2): effects on mortality and morbidity. Eur Heart J 2005;26:650–661.
  5. Prado R, Ginsburg MD et al: Hyperglycaemia increases infarct size in collaterally perfused but not end arterial vascular territories. J Cereb Blood Flow Metab 1988;8:186–192.
  6. Venables G, Miller SA, Gibson G et al: The effect of hyperglycaemia on changes during reperfusion following cerebral ischaemia in the cat. J Neurol Neurosurg Psychiatry 1985;48:663–669.
  7. Dietrich WD, Alonso O, Busto R. Moderate hyperglycaemia worsens acute blood-brain barrier injury after forebrain ischaemia in rats. Stroke 1993;24:111–116.
  8. Folbergrova J, Memezawa H, Smith ML: Focal and perifocal changes in tissue energy state during middle cerebral artery occlusion in normo- and hyperglycaemic rats. J Cereb Blood Flow Metab 1992;12:25–33.
  9. Zasslow MA, Pearl RG, Shuer LM, Steinberg GK, Lieberson RE, Larson CP Jr: Hyperglycemia decreases acute neuronal ischemic changes after middle cerebral artery occlusion in cats. Stroke 1989;20:519–523.
  10. Woo E, Chan Y, Yu Y, Huang C: Admission glucose level in relation to mortality and morbidity outcome in 252 stroke patients. Stroke 1988;19:185–191.
  11. Woo J, Lam CW, Kay R, Wong AH, et al: The influence of hyperglycaemia and diabetes mellitus on immediate and 3 month mortality and morbidity after acute stroke. Arch Neurol 1990;47:1174–1177.
  12. Feibel JH, Hardy PM, Campbell RG, Goldstein MN, Joynt RJ: Prognostic value of the stress response following stroke. JAMA 1977;238:1374–1377.
  13. Weir C, Dyker AG, Lees KR: Is hyperglycaemia an independent predictor of poor outcome after stroke? Results of a long term follow up study. BMJ 1997;314:1303–1306.
  14. Leigh R, Zaidat OO, Suri MF, Lynch G, Sundararajan S, Sunshine JL, Tarr R, Selman W, Landis DMD, Suarez JI: Predictors of hyperacute clinical worsening in ischemic stroke patients receiving thrombolytic therapy. Stroke 2004;35:1903–1907.
  15. Alvarez-Sabin J, Molina CA, Montaner J, Arenillas JF, Huertas R, Ribo M, Codina A, Quintana M: Effects of admission hyperglycemia on stroke outcome in reperfused tissue plasminogen activator-treated patients. Stroke 2003;34:1235–1241.
  16. Fogelholm R, Murros K, Rissanen A, Avikainen S: Admission blood glucose and short term survival in primary intracerebral haemorrhage: a population based study. J Neurol Neurosurg Psychiatry 2005;76:349–353.
  17. Murros K, Fogelholm R, Oppenheimer S: Hyperglycemia after stroke: a stress reaction. Stroke 1991;22:692–693.
  18. O’Neill P, Davies I, Fullerton K, Bennett D: Stress hormone and blood glucose response following acute stroke in the elderly. Stroke 1991;22:842–847.
  19. Major ongoing stroke trials. Stroke 2002;33:646–655.

    External Resources

  20. Scott JF, Robinson GM, French JM, O’Connell JE, Alberti KGMM, Gray CS: Glucose potassium insulin infusions in the treatment of acute stroke patients with mild to moderate hyperglycaemia. Stroke 1999;30:793–799.
  21. Kagansky N, Levy S, Knobler H: The role of hyperglycemia in acute stroke. Arch Neurol 2001;58:1209–1212.
  22. Heiss WD, Hayakawa T, Fink GR, Herholz K, Pietzyk U, Wagner R, Wienhard K: Progressive derangement of peri-infarct viable tissue in ischaemic stroke. J Cereb Blood Flow Metab 1992;12:193–203.
  23. Sawin C: The sliding scale of insulin use. Editorial. Arch Intern Med 1997;157:489.


Pay-per-View Options
Direct payment This item at the regular price: USD 38.00
Payment from account With a Karger Pay-per-View account (down payment USD 150) you profit from a special rate for this and other single items.
This item at the discounted price: USD 26.50